SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease and announces progress on IND enabling studies

/PRNewswire/ -- SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has exercised its option under...

Related Keywords

Italy ,Guildford ,Surrey ,United Kingdom ,Laquila ,Abruzzo ,Anna Maria Teti ,Sisaf Bio ,Suzanne Saffie Siebert ,Sue Charles ,Linkedin ,Twitter ,Vickers Venture Partners United Kingdom Future Fund ,Sisaf Ltd ,Orphan Drug Designation ,Professor Anna Maria Teti ,Distinguished Professor ,Molecular Genetics ,Indiana State University Medical School ,Chief Executive Officer ,Professor Teti ,Vickers Venture Partners ,United Kingdom Future ,Prof Teti ,Sisaf ,